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Chapter 1 
General introduction and aims
Primary hyperoxalurias (PH) are a group of rare autosomal-recessive diseases, which were
first  described in the 1920s,  but only recognized as a genetic  entity in the 1960s. The
primary hyperoxalurias are characterized by a wide clinical and genetic heterogeneity; the
clinical spectrum encompasses patients with severe nephrocalcinosis in the first year of age
and progression to diffuse multisystem oxalosis, adult patients with recurrent urolithiasis,
and even individuals still asymptomatic in late age. A proportion of cases are responsive to
vitamin  B6  supplementation,  but  the  only  effective  treatment  is  liver-  or  combined
kidney/liver  transplantation.  Liver  transplantation  is  an  invasive  and  problematic
procedure;  thus,  approaches  aimed  at  a  deeper  knowledge  of  genotype/phenotype
correlations  as  well  as  at  the  development  of  new  treatment  strategies,  appear  to  be
desirable .
From the  genetic  point  of  view,  three  types  of  Primary  Hyperoxalurias  are  currently
known: type 1 due to AGXT gene mutations, type 2 caused by GRHPR mutations and type
3, related to HOGA1. 
Although its genetic basis is known, it is still underdiagnosed even in developed countries,
and  the  knowledge  of  genotype-phenotype  correlations  is  still  inadequate  to  support
treatment choices.
The Italian study of PH1 was started in the ‘80s by Antonio Amoroso for Genetics, in
collaboration  with  Franco Linari,  Martino  Marangella,  Licia  Peruzzi  and several  other
clinicians all over Italy. More recently, the genetic diagnosis and the task of maintaining
the  Italian  Registry  of  PH1 was  transferred  to  our  Unit  at  the  San  Luigi  Hospital  in
Orbassano. 
In  2008  we  joined  OXALEurope,  the  European  Hyperoxaluria  Consortium
(www.OxalEurope.org) in order to  favour a continuous exchange of data and procedures
with other European experts involved in research and care of primary hyperoxaluria. This
collaboration has made possible to set up a common database of a cohort of more than 500
primary hyperoxaluria patients, currently the largest at international level.
Aim of  the  PhD  project  was  to  refine  the  current  knowledge  on  genotype/phenotype
correlations, to better define the therapeutic strategy in patients and to extend the molecular
analysis to HOGA1 gene, a recently described gene responsible for PH type 3.
Chapter 2
Primary Hyperoxalurias
2.1- Primary Hyperoxaluria type 1
Primary  Hyperoxaluria  type  1  (PH1)  is  estimated  to  occur  in  1:120,000  live  births  in
Europe  .  Its  prevalence  of  ranges  from 1:1,000,000  to  3:1,000,000  depending  on  the
population studied . PH1 is estimated to account for less than 1% of pediatric cases of end-
stage renal failure in Europe .
In the 1980s Danpure et al. identified the responsible enzyme of PH1: a liver peroxisomal
enzyme, the alanine:glyoxylate aminotransferase (AGT) , which catalyzes the conversion
of glyoxylate to glycine. When AGT activity is absent, glyoxylate is converted to oxalate,
which forms insoluble calcium salts (oxalate cannot be metabolized in mammals). 
aldolasi 
As all aminotransferases, AGT is a pyridoxal phosphate-dependent enzyme. The protein
(392aa) has a homodimeric 86kDa structure , that was solved by X-ray crystallography by
Zhang et  al.  in 2003. Figure 2.2 shows a three-dimensional  representation of the AGT
dimer where the mitochondrial  targeting sequences (pink),  the N-terminal  alpha helical
stretch (green), the PLP cofactor (orange) and the sites of most frequent mutations (blue)
are highlighted.
Figure 2.1: The Metabolic Pathways of Oxalate Production in Humans, modified from 
Danpure et al., 2004 
The protein is synthesized in the hepatocite  ribosomes; the monomers fold and rapidly
dimerize in the cytosol. The dimerization allows the peroxisome import and the conversion
in a fully active state. The first 20 residues make an N-terminal extension that wraps over
the surface of the cognate subunit. The next 260 residues form the catalytic domain that
contains most of the active site and the dimerization interface. The C-terminal of about 110
residues contains the peroxisomal targeting information. Each subunit binds one pyridoxal-
phosphate molecule (PLP), which forms a Schiff base with Lys209. Monomeric AGT has a
vastly reduced catalytic activity, is unstable and rapidly aggregates and is degraded .
AGT is encoded by the human alanine-gloxylate-aminotransferase (AGXT) gene, located
on chromosome 2q37.3 (11 exons, NM_000030.2 http://www.ncbi.nlm.nih.gov/).  (Figure
2.3).
Figure 2.3: AGXT location. 
Normal human AGT exists as two polymorphic variants: the ‘‘Major’’, more common, and
the ‘‘minor’’, less common, allele. Major allele has a 80% frequency among individuals of
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European origin and the minor one a 20% frequency in Europeans, 2% in Japanese, 3% in
South African Blacks .
The  minor  allele  is  characterized  by  several  SNPs  in  linkage  disequilibrium  among
themselves,  notably  p.Pro11Leu,  p.Ile340Met  and  a  74-bp  duplication  in  intron  1
(c.165+14_+88del74).  The  only  variant  of  functional  significance  is  the  p.Pro11Leu
aminoacid substitution at the N-terminal, which is thought to permit formation of an  α-
helical conformation similar to that found in proteins normally targeted to the mitochondria
. In the absence of a disease-causing mutation, this mitochondrial targeting of the minor
allele  is  of scarce or no clinical  significance.  However,  when in cis with some AGXT
mutations, such as p.Gly170Arg, it has a synergic effect and results in mistargeting of the
protein to the mitocondria (Fig. 2.4).
Figure 2.4: 
A:  AGT encoded  by the  major  AGXT allele  folds  and
dimerizes very rapidly. 
B: AGT encoded by the minor AGXT allele: despite the
greater  import  potential  to  mitochondria  that  to
peroxisomes, most AGT is prevented from being targeted
to  mitochondria  by  its  still  faster  rate  of  folding  and
dimerization.  Therefore,  most  AGT  are  imported  into
peroxisomes  and  only  a  small  proportion  (5%)  into
mitochondria. 
C:  PH1  mutant  AGT  containing  both  the  Pro11Leu
polymorphism and the p.Gly170Arg mutation: the double
substitution inhibits folding and/or dimerization.
Therefore, newly synthesized AGT spends a longer time
in  a  conformation  compatible  with  the  mitochondrial
import  machinery.  Most  of  the  AGT  is  targeted  to
mitochondria..
2.2- Primary Hyperoxaluria type 2
Primary Hyperoxaluria type 2 (PH2, OMIM# 604296) accounts for 5 to 17% of PH cases. 
Infantile oxalosis and systemic oxalosis are not reported in PH2 patients, although ESRD
occurs  in  approximately  20% .  The low prevalence  of  PH2 does  not  allow genotype-
phenotype correlations at the present time.
PH2  is  caused  by  deficiency  of  the  ubiquitous  enzyme  glyoxylate-
reductase/hydroxypyruvate-reductase (GR/HPR), a bifunctional enzyme that catalyzes the
reduction of glyoxylate and hydroxypyruvate (Figure 2.4). The lack of GR leads to oxalate
accumulation, as a result of impaired glyoxylate conversion to glycolate. Excess oxalate is
then degraded by LDH.
Lack of HPR action is responsible for hydroxypyruvate accumulation,  which is in turn
converted  into  L-glicerate.  Therefore,  the  elevation  of  urinary  L-glyceric  acid  is  the
biochemical marker of PH2 . The diagnosis is confirmed by the finding of two mutated
GRHPR alleles.
The normal GR/HPR enzyme is a homodimer (Figure 2.5) with a large coenzyme-binding
domain (residues 107-298) and a smaller substrate-binding domain (5-106 and 299-328) . 
Figure 2.5: Overall structure of the human GRHPR. (a) Cα trace of a single subunit, subunit
A shown in blue; co-enzyme and substrate in cyan and labeled. The amino and carboxyl
termini are labeled N and C, respectively. (b) Cα trace of a
GRHPR dimer; subunit A is shown in blue, and subunit B
in  green.  The  Trp141  side-chain  is  shown  in  stick
representation in yellow and is labeled; and the co-enzyme
and substrate are in cyan and also labeled. (c) Overlay of a
single  subunit  of  GRHPR  (subunit  A;  blue)  with  CtBP
(red), D-LDH (green), FDH (yellow) and bacterial D-GDH
(cyan) .
A prominent extended helix-loop region wraps around the
other  subunit  (dimerization  loop,  residues  123-149).  The
apex of this loop contains a tryptophan residue at position
141 and the residue from one subunit is projected into the
active site of the other subunit and contributes to substrate
specificity. The protein is found primarily in the cytosol although some immunoreactivity
has been found in mitochondria. 
All the missense mutations described to date result in proteins with no catalytic activity . 
Figure 2.6: GRHPR gene (9p11.2; 9 exons).
2.3- Primary Hyperoxaluria type 3
Primary hyperoxaluria  type 3 (PH3, OMIM#613616) was identified in 2010 and arises
from homozygous or compound heterozygous mutations in the HOGA1 gene (formerly
DHDPSL) . 
No data on PH3 prevalence are available. A German study reported a 30% prevalence of
PH3 among patient with a clinical diagnosis of non PH1-nonPH2 . 
The HOGA1  gene (10q24.2) spans 7 exons (327aa); two HOGA1 transcripts have been
described: one transcript is composed by all 7 exons and the second one, shorter, lacks the
central part . 
Figure 2.7: HOGA1 gene (10q24.2).
HOGA1 encodes the 4-hydroxy-2-oxoglutarate aldolase enzyme, responsible for the final
step  of  mitochondrial  hydroxyproline  metabolism  (Figure  2.8)  from  4-hydroxy-2-
oxoglutarate to glyoxylate and pyruvate . 
The enzymatic
block leads to an  increase
of  the  4- hydroxy-2-
Figure 2.8: The metabolic pathway of Hydroxyproline degradation in humans . 
oxoglutarate (HOG) substrate, which can be found in elevated levels in the urine, plasma,
and liver of PH 3 patients .
 
The HOGA enzyme is a homotetramer (two dimers). Each monomer is composed by a
TIM  barrel  domain  (residues  26  -  259)  and  a  three-helical  bundle  at  the  C-terminus
(residues 260 - 327). The active site is located at the C-terminal end of the TIM barrel
domain  near  the  monomer-monomer  interface  of  the  ‘‘tight’’ dimer  (colored  different
shades of orange and gray in Figure 2.9). Critical residues for the active site function (Tyr
168, Lys 196) and for catalysis (Ser77, Asn78, Ser198) were identified. HOGA1 mutations
currently  described  in  PH3 patients  disrupt  the  active  site  (e.g.  Arg70Pro,  Arg97Cys,
Pro190Leu, Thr280Ile, Gln287Val) or the tetramerization (Cys257Gly) .
Figure 2.9: Structure of human HOGA. (A) Homo-tetrameric
organization of hHOGA. The tetramer consists of a dimer of
dimers  (orange and gray).  (B) The hHOGA monomer.  Two
orthogonal views illustrate the overall architecture, TIM barrel
fold,  and C-terminal  helical  bundle.  Coloring is  as  follows:
gray, a-helices; orange, b-strands; lightorange, loop regions .
The precise mechanisms underlying the hyperoxaluria are still
not fully understood and different models have been proposed.
The  leakage  of  HOG  from  the  mitochondrial  compartment
into the cytosol,  where a yet-to-be identified aldolase will  convert  HOG again into the
highly reactive oxalate precursor glyoxylate has been proposed. Another factor that may
significantly contribute to increased oxalate generation could be the recently reported inhi-
bition of mitochondrial GRHPR by excess of HOG .
 
From a  clinical  perspective,  PH3 is  also  unique:  clinical  remission  is  observed  in  the
majority  of  patients,  without  a  parallel  biochemical  remission.  Moreover,  a  peculiar
biochemical  aspect  of  PH3 is  the  presence  of  a  marked hypercalciuria.  Early  onset  of
calcium-oxalate urolithiasis that becomes more and more quiescent with age, the presence
of  intermittent  hypercalciuria  (never  seen  in  PH 1 and 2),  and the absence  of  marked
nephrocalcinosis  and renal  insufficiency seem to be characteristics  of PH 3  . Although
several studies encompassing about 50 patients confirmed the absence of CKD/ESRD, this
finding should still be considered preliminary .
2.4- Symptoms
Oxalate  is  mainly  eliminated  via  the  kidneys,  but  urine  easily
supersaturates.  Calcium oxalate  accumulation  in  the  kidneys and
other organs leads to end-stage renal disease (ESRD) and systemic
oxalosis. 
The presentation of PH is variable, with reported age at onset of symptoms ranging from
birth  to  57  years  :  these  characteristics  are  responsible  for  an  under-diagnosis  of  this
disease, as demonstrated by the high proportion (up to 30%) of late diagnosis in advanced
renal  failure  or  after  failure  of  kidney  transplantation.  Usually  the  first  symptoms  are
related to the presence of renal stones : colic pain, hematuria, dysuria, recurrent urinary
tract infections and, in some cases, renal failure. 
Oxalosis  is  the  deposition  of  oxalate  in  a  variety  of  tissues  and  it  occurs  when  the
Glomerular  Filtration  Rate  (GFR)  is  less  than  60mL/min/1.73m2 and  plasma  oxalate
concentration exceeds 20uM . 
Main tissues involved in systemic oxalosis are : 
 kidney and urinary tract (Figure A and B)
 bone and bone marrow (Figure C): bone is 
the largest repository  for excess oxalate. 
Deposition may lead to pain, multiple fractures,
arthropathy, osteosclerosis pancytopenia and
erythropoietin-resistant anemia  
 Eye (Figure D): retinopathy, optic atrophy
 Teeth: root reabsorption, pulp exposure, dental pain
 Nerves: peripheral neuropathy (axonal degeneration 
and segmental demyelination), brain and meninges. . 
 Heart and vessels: conduction block, 
myocarditis, cardioembolic stroke, vasospasm,
livedo reticularis, vessel calcification, peripheral gangrene
 Calcinosis cutis D
 
A
B
Oxalate crystal
 Hepatosplenomegaly 
2.5- Diagnosis
The first confirmation of PH is given by biochemical testing : the routine test is based on
the measurement of oxalate in 24-hour urine collection, or in plasma for patients in ESRD.
Normal urinary oxalate excretion is less than 0.46 mmol/1.73 m2/24h.
In PH1 the urinary oxalate excretion tends to be higher (2.14±1.29 mmol per 1.73m2 per
day) than in PH2 (1.46±0.49mmol per 1.73m2 per day). 
Oxalate urinary excretion differs between males and females and is not stabilized until ages
14 to 18 years (Table 2.1). 
Table 2.1: Urinary Oxalate levels diagnostic for PH1 in children  
Age Urinary oxalate [umol/mmol cr]  
< 6 months > 370
6 months - 2 years > 260
2 – 5 years > 140
5 - 12 years > 80
Approximately 66% of individuals with PH1 also have a high concentration of glycolic
acids  in  plasma  and  urine  (hyperglycolic  aciduria)  .  Moreover,  an  elevated  plasma
glycerate level may be helpful for distinguishing PH1 from PH2 (Table 2.2).
Table 2.2 Normal Values for Urinary Oxalate, Glycolate, and L-Glycerate Excretion in
24-Hour  Urine  and  Spot  Urine  Samples.  Adapted  from  .  1Values  are  laboratory  and
method dependent.  2To prevent alkaline conversion of ascorbate to oxalate in urine, the
sample  must  be  strongly  acidified  to  stabilize  ascorbate  and  minimize  formation  of
calcium crystals .
Parameter Age Normal Values 1 
In 24-hour urine sample
Urinary oxalate excretion 2
All ages
<0.50 mmol (<45 mg)/1.73 m2/day
Urinary glycolate excretion <0.50 mmol (<45 mg)/1.73 m2/day
Urinary l-glyceric acid excretion <5 μmol/L
In spot urine sample
Spot  urinary  oxalate-to-creatinine
molar ratio 2
0-6 mos 
7-24 mos 
2-5 yrs
5-14 yrs
>16 yrs
<325-360 mmol/mol
<132-174 mmol/mol
<98-101 mmol/mol
<70-82 mmol/mol
<40 mmol/mol
Spot  urinary  glycolate-to-creatinine
molar ratio
0-6 mos 
7-24 mos 
2-5 yrs
5-14 yrs
>16 yrs
<363-425 mmol/mol
<245-293 mmol/mol
<191-229 mmol/mol
<166-186 mmol/mol
<99-125 mmol/mol
Spot urinary l-glycerate-to-creatinine
molar ratio
< 5 yrs
5-14 yrs
>16 yrs
14-205 mmol/mol
23-138 mmol/mol
<138 mmol/mol
In patients with renal insufficiency plasma oxalate and gycolate measurement is preferable.
Normal ranges are defined for the specific assay used  and are affected by the degree of
renal dysfunction and the dialysis (Table 2.3).
Table 2.3: Oxalate and glycolate levels diagnostic for PH1 in ESRD 
Renal insufficiency
(GFR<60ml/min/1,73m2)
Plasma oxalate >60 μmol/l Plasma glycolate>10 μmol/l           
Assay  of  AGT catalytic  activity  in  liver  biopsy  was  considered  the  gold  standard  for
diagnosis. Now, it has been largely replaced by molecular genetic testing, which is easier to
perform and less dangerous for the patient. 
Molecular genetic testing of the three genes on blood DNA is now used for confirmation of
the clinical diagnosis. 
The identification  of mutation carriers makes a presymptomatic  diagnosis  possible  and
opens the opportunity to address mutation carriers to an appropriate genetic counseling.
2.6- Treatment
Basically, the conservative treatment of PH has not improved over the last 20 years, despite
fundamental insights regarding molecular mechanisms and pathophysiology of the disease.
Reduction of calcium oxalate supersaturation. The general therapies for nephrolithiasis
benefit  all  individuals  with  PH:  large  volumes  of  fluid  (2-3  L/m2/24  hours)  at  regular
intervals  over  the  entire  day/night  prevent  calcium  oxalate  supersaturation  .
Supplementation  of  dietary  calcium  with  300  mg  calcium  at  each  meal  significantly
decreases  urinary  calcium  oxalate  without  altering  calcium  excretion  .  Drugs  such  as
thiazides and potassium citrate or neutral orthophosphates can decrease urinary calcium
excretion and inhibit stone formation, respectively .
Enzyme reactivation therapy in PH1. AGT is a pyridoxal-phosphate (PLP)-dependent
enzyme.  It  is  well  known that  specific  genotypes  (e.g.  p.Gly170Arg,  p.Ile244Thr  and
p.Phe153Ile   respond  to  treatment  with  pyridoxine  (vitamin  B6,  precursor  to  PLP).
Response  to  treatment  is  defined  by  a  greater  than  30% reduction  in  plasma  oxalate
concentration  or  normalization  of  urinary  oxalate  excretion  within  three  months  of
therapy . 
Dialysis. Standard dialysis  protocols are not sufficient to reverse, nor even stabilize an
affected individual's oxalate burden. Intensified dialysis protocols can be more effective
but this intensity of care is difficult to maintain over the long term .
Organ  transplantation.  Isolated  kidney  transplantation  restores  oxalate  excretion  to
"normal" and could be used in all the three types of PH . Isolated kidney transplantation in
PH1 is used in individuals with full pyridoxine responsiveness or very slow progression of
their disease  .
Liver transplant is used in PH1, since it can restore the AGT function (AGT is a liver-
specific enzyme).  Currently, "preemptive" liver transplantation is used before end-stage
renal disease (restores enzyme activity, decreases ongoing oxalate synthesis). Combined
liver-kidney transplantation, either concurrent or sequential is used in ESRD patients  .
Therapies Under Investigation
-  Oxalate-degrading  bacteria.  Oxalobacter  formigenes,  a  normal  component  of  the
intestinal flora, is able to degrade intestinal oxalate , thus reducing the amount of oxalate
available for intestinal absorption  . O. formigenes is also thought to stimulate secretion of
endogenous oxalate into the intestine for its own metabolic use . 
During the past three decades it has been proved that the intestine plays an important role
in  oxalate  homeostasis  and  that  Oxalobacter  formigenes can  regulate  oxalic  acid
absorption in the gut .
Two  pilot  trials  with  orally  administered  Oxalobacter  formigenes in  PH  patients
demonstrated a reduction of urine or plasma oxalate levels . A multicenter Phase III trial is
ongoing in PH patients with EGFR > 40ml/min to determine the efficacy of this bacterium
in reducing oxalate excretion (ClinicalTrials.gov Identifier:  NCT02012985). One of our
Italian patients is enrolled in this study. Another open-label study is beginning, aimed to
evaluate  plasma oxalate  reduction  in  PH patients  already  in  ESRD (ClinicalTrials.gov
Identifier: NCT02000219).
-  Hepatocyte  transplantation. Repopulation  of  the  liver  with  normal  or  genetically
corrected  hepatocytes  could  correct  the  disease  and  it  is  less  invasive  than  liver
transplantation. However, host cells must be ablated as they would continue to produce
oxalate  and the  donor  hepatocytes  would  then  require  a  growth  advantage  to  achieve
repopulation. The effectiveness of this approach has been demonstrated in a mouse model
of PH1 . 
-  Gene therapy.  Salido et  al.   demonstrated that  hepatic  expression of human AGT by
adenoviral  vector-mediated  gene  transfer  in  Agxt-/-  mice  normalized  urinary  oxalate
excretion and prevented oxalate crystalluria.
- Chemical chaperones. The majority of the most common alleles associated to PH1 affect
protein folding and stability, suggesting that most PH1 patients may show defective AGT
function due to alterations  in its  protein homeostasis.  Salido et  al  delineated  important
checkpoints in AGT protein homeostasis, such as the stability of the apo-proteins and the
recognition of folding intermediates by molecular chaperones that might be specifically
targeted to restore AGT function in PH1 patients. They showed that several PH1 mutations
of  the  minor  haplotype  strongly  interact  with  Hsc70  chaperones,  and  they  previously
demonstrated that they can correct the mitocondrial mistargeting (in p.G170R mutation)
and prevent the aggregation induced by the p.I244T mutation . Hsp70, Hsp60 and Hsp90
chaperone systems are known to cooperate in assisting protein folding  and they could be
potential targets for correction of the folding defects displayed by PH1 mutants . 
-  Substrate  reduction  therapy  through  RNA-interference.  A US company  (Dycerna)  is
developing a RNA-interference based technique that has been shown efficient in AGXT
knockout mice and in PH1 monkey model. The first trial in human is expected to begin by
June 2015.
2.7- Differential Diagnosis
PH1 accounts for 70-80% of PH cases, while PH2 and PH3 are rarer. 
Other  subtypes  of  primary  hyperoxaluria  termed  non  PH1/2  or  atypical  PH are
increasingly reported, since 10% of patients with a phenotype compatible with PH do not
show mutations in the known genes.  The pathophysiology of atypical  PH is  unknown,
making therapy and counseling extremely difficult. 
 
-  PH must  be  differentiated  from secondary  forms  of  hyperoxaluria  where  a  different
underlying disorder causes increased absorption of dietary oxalic acid. Diseases affecting
the small bowel, such as celiac disease, Crohn's disease and short bowel syndrome can be
associated with hyperoxaluria. The precipitation of enteric calcium by non-absorbed free
fatty  acids  leads  to  loss  of  normal  inhibition  in  oxalate  reabsorption  from  the  gut,
increasing  plasma  oxalate  concentration  by  increasing  paracellular  and  transcellular
transport. Delivery of excess fatty acids and bile salts to the colon also injures the mucosa
and  increases  oxalate  absorption  .  Gastric  bypass  procedures  used  in  the  treatment  of
obesity have been associated with increased oxalate absorption, pronounced hyperoxaluria,
and increased risk of kidney stone formation . The [13C2]oxalate absorption test has proven
a valuable tool for differentiation the two conditions.
- Dent disease is a rare genetic renal tubular disease characterized by manifestations of
proximal  tubule  dysfunction  (low-molecular-weight  proteinuria  and  hypercalciuria),
nephrolithiasis,  nephrocalcinosis,  and progressive renal  failure.  Differential  diagnosis is
based on the  presence  of  hypercalciuria  and low-molecular-weight  proteinuria  in  Dent
disease.
- Hyperoxaluria has been described in total parenteral nutrition in premature infants  and
adults  and in peroxisomal disorders . 
Chapter 3 
The Italian database
3.1 - General description of Italian Cases
Since the beginning of PH molecular diagnosis in Italy efforts were made to collect the
clinical data of the Italian PH patients. In the last few years an Italian PH database was
created  to  systematically  register  genetic  and  phenotypic  data  for  each  PH  patient.
Phenotypic data were collected at onset and at follow up. All the data were transferred to
the European data base in 2013.
At the end of 2014 the Italian database includes 80 PH1 patients (28 females and 52 males)
and 2 PH2 patient.  Median age of  the  cohort  is  22 years  old  (I-III  quartile:  11-35,3).
Thirteen  patients  (16%)  have  consanguineous  parents  (for  16  patients  (20%)  this
information is not available). In 30 cases a familial history of PH is reported.
Symptoms  at  onset  are  mainly  nephrolithiasis  (NL  -  42  patients  –  52,5%)  and
nephrocalcinosis (NC- 26 patients – 35,2%), as generally reported in PH patients. Three
patients were diagnosed at family screening before symptoms development. Median age at
onset is age 4 years (0.5-11,5), median age at diagnosis is 11 years old (4-30). 
Biochemical measurements at diagnosis were not available for 11 patients. For the other
patients it was available the plasma or the urinary oxalate dosage (plasma dosage is more
difficult, so it is usually preferred the urinary dosage. Urine dosage is not feasible in ESRF
patients). Median plasma oxalate at diagnosis is 130 umol/L (24-187; data not available in
23 patients)  and median urinary oxalate  is  230 uM/mM creat/24h (151-435,5; data not
available in 41 patients). Glycolate dosage is no longer available, so median value were
calculated  among  few patients:  median  plasma  glycolate,  available  for  27  patients,  is
183umol/L(125,5-  366,0)  and  median  urinary  glycolate,  available  for  20  patients,  was
319uM/mM creat/24h (184,5-463,0)
Liver biopsy for AGT activity measurement was available for 35 patients (liver biopsy is
now substitute by genetic testing, that is more reliable and less invasive). Mean residual
AGT activity was negligible in 27 patients and only in 8/35 (22,9%) samples a partial AGT
activity was detected (mean activity: 39±13% of the normal). 
At the end of 2014, 55 patients have had ESRF. Median age at ESRD is 14 years of age (4-
31).
Ten patients had a kidney-only transplant and, among them, 2 had a second kidney-only
transplant.  In  other  6  cases  the  second  kidney  transplant  was  combined  with  liver
transplant. Median age at first kidney transplant was 18 years old (10-35). 
In 17 patients a combined kidney-liver transplant was performed and in one a sequential
kidney-liver transplant. Median age at kidney-liver transplant was 13 years old (4-27). In 2
cases  a  second kidney  transplant  was  performed after  the  combined  kidney-liver.  One
patient underwent two combined kidney-liver transplants. In one case a preemptive liver
transplant was performed.
Some recurrent mutations are present (Figure 3.1). As reported in literature,  also in the
Italian  cohort  the  most  common mutation  is  p.Gly170Arg  (28% of  the  alleles),  in  14
patients in homozygosis, in 11 in heterozygosis with a missense mutation and in 4 with a
null mutation.
Figure 3.1: AGXT mutations in the Italian cohort
Some mutations are recurrent among not related patients belonging to the same geographic
area. Therefore, for these mutations we were able to recognize a founder effect (Figure
3.2). 
Figure 3.2: mutation distribution
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3.3 - HOGA1 and GRHPR genes analysis
In order to increase the detection rate of mutations in PH patients referred to our Centre we
set up the analysis of the entire AGXT (including the promoter), of GRHPR and HOGA1
genes.
HOGA1 and GRHPR analysis is performed by direct sequencing the 5’ and 3’ UTR, the
coding  sequence  and  exons-introns  junctions  of  isoform  1  (HOGA1  RefSeq:
NM_138413.3; GRHPR RefSeq: NM_ 012203.1).
Amplimers Length
(bp)
Forward Primer Reverse Primer
Exon 1 672 CTGGCTTCAGAGCTGGGAAT AGCTGTCCAGGGATAGTCTGG
TAC 
Exons 2+3 811 ATGGTTGAGCCACTGCATC CACGACATTGGGAGGCTTA 
Exons 4+5 744 AGGTGGCCCTGTAGTGAAGC ACTCAGAAACCTGGCCACG 
Exon 6 417 ACAGAGCATGCCTTTGATGTAG GAGAGAACATCCCAGTGTG 
Exon 7 400 ACTTCAATGTTCTGAAAGTGACAGA AGGCAGCCTTTCACAGG 
Table 3.1:  HOGA1 PCR: amplimers length and forward and reverse primers sequences;
sequencing primers in bold. 
Amplimers Length
(bp) 
Forward Primer Reverse Primer 
Exon 1 308 TCCCTCTCGCGAAGCCACA GGCCACAAGGCCCAAACG 
Exon 2 375 CCATCAGAGGCCAGGATTC CTGTGCCAGAGCAAGCTATC 
Exon 3 410 AGGCCCTGAGGTGAACCC CTGAATGGCCGAGGGATATG 
Exon 4 278 TGGAAATGTCCCAGCAGTAGA CTCCTAACCTCTAGATCCGC 
Exon 5 252 GACCTGGAGGGTGGGTTTAT AAACCACGCTGTGAGAGCC 
Exon 6 260 CTGTGCTGATGAAAAGGGTCT CAAACTGGGCACAGATAGGC 
Exon 7 287 CGCCATCTGGTTGTCCCTAG CACCAACAACCCACGGG 
Exon 8 274 TTCATTCTGTAGGTTGTTCTGCC CTCAAAAACACTGGTCCTGTC 
Exon 9 257 GCTGAAGGCTGCTGAACC GATCCAAATCAAGCCTGGG 
Table 3.2:  GRHPR PCR: amplimers length and forward and reverse primers sequences;
sequencing primers in bold.
Twenty-four patients with high clinical suspicion of PH, but negative for AGXT mutations
type  1  patients  referred  to  our  Unit  were  selected  on  the  basis  of  their  on  clinical
characteristics  (presence  of  nephrolithiasis  and/or  nephrocalcinosis,  age  at  onset  <  15
years),  biochemical  parameters  (oxalemia  >  80  mmol/L,  urinary  oxalate  and glycolate
levels as shown in tab.1, reduction of renal function) and absence of identifiable cause of
secondary  hyperoxaluria  (intestinal  malabsorption,  inflammatory  bowel  diseases,  etc.).
Nine non-PH1 patients  were excluded from this  study because of a  different  diagnosis
made  after  AGXT testing  (four  patients  were  affected  with  secondary  forms  of
hyperoxaluria, three by kidney malformations, one received a diagnosis of Dent syndrome
and one of Pseudo-Bartter syndrome). Fifteen probands were thus included.
All patients or their legal representatives gave informed consent for the present genetic
analysis.
The  15  patients  analysed  (six  males  -  40%  and  nine  females  -  60%)  have  clinical
characteristic comparable with the PH1 cohort: mean age at onset of symptoms is 5,3 years
(range: 2 months - 32 years), 74% have nephrolithiasis,  33% nephrocalcinosis  and one
patient  is  affected  by  both  (Table  3.3).  Renal  function  was  normal  in  nine;  three  had
already progressed to ESRD (data not available for three patients). 
Mean oxaluria calculated on values of eight patients was 103.86 mMol/mMol creatinine
(range: 55-209) and 0.92 mMol/24h (normal range: 0.51 - 1.78). In the patients in ESRD
state the mean serum oxalate was 15.8 µmol/L (normal range: 1 - 65.2).
According to recent  guidelines  ,  even if  the  AGXT  genetic  test  resulted negative  these
findings supported the suspicion of PH, and prompted for further molecular analysis.
Table 3.3: patient analysed in the study
ID gender
Age at
last
FU
Age at
onset of
sympt.
ESRD
at last
FU
Urinary
oxalate
uMol/m
Mol crea
Urinary
Calcium
Plasma
oxalate
uMol/L
Clinical
presentationmEq/
L
Ca/
crea
1 M 44 y 32 y Yes   
 
80
Bilateral 
nephrolithias
is
2 F 13 y 9 y No 70  5,6 Nephrolithiasis
3 M 46 y 3 y Yes   16 nephrolithiasis 
4 M 4 y     nephrocalcinosis
5 F 6 y 6 mo Yes 106
  
4
nephrolithias
is, ematuria,
  urinary tract infection
6 M 4 mo 2 mo No 366 1,0 5,6  Nefrocalcinosi
7 F 16 y 9 y No 86 2,1 1,2  
nephrolithias
is, urinary 
tract 
infection
8 F 3 y 4 mo No 115   10
nephrolithias
is, 
nephrocalcin
osis, 
hematuria
9 F 5 y 2 y No 180
  
 nephrolithiasis  
10 M 2 y 6 y No 205    
Bilateral 
nephrolithias
is, 
hematuria, 
11 M 37 y 7 y Yes     Nephrolithiasis
12 F 3 y 1 y 190 8,2  6 nephrolithiasis, hematuria
13 M 2 y 14 mo No 170 2,1 1 9
Nephrocalci
nosis and
Nephrolithia
sis
14 F 13 y 9 y No  0,8 0,2  
nephrolithias
is, urinary 
tract 
infection
15 M 1 y 2 mo     
nephrocalcin
osis,  urinary
tract 
infection
The GRHPR and HOGA1 analysis in the 15 patients give a normal result. Heterozygous
SNP are reported in the following table 
Patient n°6 is homozygous for the HOGA1 variant c.341-81delT in intron 2 (Fig. 3.3). The
presence of HOGA1 variant was validated by bidirectional resequencing of an independent
PCR product and described according the Human Genome Variation Society guidelines.
GRHPR HOGA1
ID Result Heterozygous SNP Result Heterozygous SNP
1 WT rs10973332:C>A WT
rs11817730:A>G
rs7078003:C>T
rs2297644:C>T
2 WT - WT -
3 WT rs35891798:G/-rs10644334:CT(8_9) WT -
4 WT rs10973332:C>Ars10644334:CT(8_9) WT rs11527932:G>T
5 WT rs10644334:CT(8_9) WT -
6 WT rs10644334:CT(8_9) UV -
7 WT - WT
rs11817730:A>G
rs7078003:C>T
rs297644:C>T
rs12261752:A>C
8 WT - WT rs75929214:C>Trs12261752:C>A
9 WT rs35891798:G/-rs76299266:G>A WT rs12261752:C>A
10 WT rs10644334:CT(8_9) WT
rs75929214:C>T
rs2297643:A>G
rs12261752:C>A
11 WT - WT
rs2297643:A>G
rs115279832:G>T
rs12261752:C>A
12 WT rs35891798:G/-rs10644334:CT(8_9) WT -
13 WT - WT rs75929214:C>T
14 WT - WT rs75929214:C>Trs74155508:G>C
15 WT - WT
rs11817730:A>G
rs75929214:C>T
rs7078003:C>T
rs2297644:C>T
A) 
AGAGGATGGGAAGGAGTTRGTCAGCTGTGTCTCTTGCAGGCTTCGTGGTCCAGGGCTCCA esone
2
ATGGYGARTTTCCTTTCCTGACCAGCAGTGAGCGCCTCGAGGTGGTGAGCCGTGTGCGCC
AGGCCATGCCCAAGAACAGGCTCCTGCTAGCTGGCTCCGGATGCSAGTGTGAGCCAGAAT 
intron 2
GCCCTGGGCCCTGSGGGTGGGTGGATGTGCAGGATCCAGGCTCCTAGGCCCTAGCTTGGG 
TCCTGTCTCCTTGTTCTGCYTCTTCTGGGACATGCTGAGGCACCTTCGCTTGGCCCAGTG 
TCCTGGTCCAGGCCTCCTTCTGCCTGCTCTCACCTCTCTCCTTCCTCTGGCAGCCACTCA exon 
3
AGCCACAGTKGAGATGAYCGTCAGCATGGCCCAGGTCGGGGCTGACGCRGCCATGGTGGT
GACCCCTTGCTACTATCGTGGCCGCATGAGCAGYGYGGCCCTCATTCACCRCTACACYAA
GGTGTGTGTGAGGCCTGAGACCAAGAGGAGGCTCTGCCCAGGGAGAGGAGATAAGGGAAG 
intron 3
B) 
          
         
Figure 3.3: c.341-81delT variant in HOGA1 intron 2
- HOGA1 sequence: exon 2, intron 2, exon 3. Common SNP are highlighted in green
- Chromatograms of the wild-type (top) and c.341-81delT deletion (bottom).
The  c.341-81delT  variant  isn’t  reported  in  literature  in  PH  patients  nor  in  the
1000Genomes populations (http://www.1000genomes.org). 
Intron  2  sequence  is  conserved  through  primates  but  not  in  other  species
(http://genome.ucsc.edu/cgi-bin/hgc) (Fig. 3.4).
Functional enzyme analysis is not possible: the patient died at 4 months of life because of
respiratory failure.
Figure 3.4: HOGA1 Intron 2 evolutionary conservation.
In silico analyses postulate that the T deletion in c.341-81 generates an acceptor splice site
(AG  in  c.341-79),  possibly  recognized  by  the  spliceosome;  moreover,  the  upstream
sequence, rich in T and C, is similar to the 3' consensus sequence (Fig. 3.5).
AGGCCATGCCCAAGAACAGGCTCCTGCTAGCTGGCTCCGGATGCCAGTGTGAGCCAGAAT
GCCCTGGGCCCTGGGGGTGGGTGGATGTGCAGGATCCAGGCTCCTAGGCCCTAGCTTGGG
TCCTGTCTCCTTGTTCTGCCTCTTCTGGGACATGCTGAGGCACCTTCGCTTGGCCCAGTG
TCCTGGTCCAGGCCTCCTTCTGCCTGCTCTCACCTCTCTCCTTCCTCTGGCAGCCACTCA
Figure 3.5: in black: HOGA1 intron 2 sequence; in pink: part of exons 2 e 3. c.341-81 is 
highlighted in red, the putative new acceptor splice site in yellow, in green: normal donor 
and acceptor splice site. In light blue: the normal consensus sequence, in grey the C-T 
reach sequence, similar to the normal consensus sequence
The following table summarizes the probability scores of the new splice site recognition. 
               Software Range values Score Probability
SSF  0-100 78,17 78,17%
Max Ent 0-16 7,95 49,7%
NN Splice 0-15 < 0,4 < 2,6%
Gene Splicer 0-15 6,59 43,9%
HSF 0-100 82,5 82,5%
Four out of five software predict a possible damaging role of the variant; the alternative
splicing  is  predicted  to  produce  a  transcript  79 bp longer  (r.340_341ins341-79_341-1),
which includes part of intron 2. This could lead to a shift in the reading frame, responsible
for the production of a truncated protein (premature stop codon at the beginning of exon 3:
p.Thr115Glufs*43) (Fig.3.6).
Figure 3.6: A) Wild type nucleotidic and aminoacidic sequence; 
B) nucleotidic and aminoacidic sequence with the frameshift; in green: translated part of 
intron 2, in red: stop codon. 
The c.341-81delT variant isn’t predicted to alter HOGA isoforms 2 and 3, because these
isoforms didn’t  includes  exons  2 and 3  translation.  These  two isoforms are  likely  not
functional. 
In order to clarify the role of the c.341-81delT variant we decided to set up an in vitro
approach, using a previously described technique (Cavalieri  S. et  al,  Eur J Hum Genet
2012). With the collaboration of Alessandra Cuccurullo, BS and Prof. Brusco a minigene
assay was set up to test the effect of the HOGA1 c.341-81delT variant on splicing. 
We amplified a 449-bp genomic fragment from Patient 6 and a wild type control, using the
following  primers  Forward:  5’-ACTGGAATTCGTGGGTGGATGTGCAGGAT-3’;
Reverse:  5’-GGTCAGGTAAGCCTCCCAAT-3’.  PCR products  were  cloned into  a  TA-
vector (pGEM-T Easy Vector - Promega, Madison, WI, USA) (Fig.5) and transformed in
DH5a bacterial  cells,  following the manufacturer’s  recommendations  (RBC Bioscience,
Chung Ho City, Taiwan). 
Figure 3.7: scheme of the TA vector. 
Plasmids  containing  the  wild  type  or  the  variant  sequence  were  extracted  using  the
PureYield plasmid system (Promega) and sequence checked. After preparative digestion
with EcoRI restriction endonuclease, inserts were sub-cloned into a pSPL3 exon-trapping
vector (Life Technologies, Paisley, UK) (Fig. 3.8). The insertion orientation was checked
by PCR using  a  Forward  primer  designed on pSPL3 together  with  each of  the  above
mentioned PCR primers; we selected the plasmids with the correct orientation (amplified
with the PCR reverse primer).
Figure 3.8: sPSL3 expected splicing. Fragments of the human HOGA1 gene containing
exon 3 were cloned into the splicing vector pSPL3 generating plasmids pSPL3-HOGA1-
Exon3-WT and pSPL3-HOGA1-delTExon3. The blue boxes mark pSPL3 exons A and B
(derived  from the  B-globin  gene)  with  the  adjacent  black  lines  depicting  the  flanking
intronic sequence of the pSPL3 exons. The green box marks HOGA1 exon 3. The red box
represents the 79bp insertion expected from the generation of a novel splice-site by the
c.341-81delT variant. The interrupted black lines mark the spliced out intronic sequences.
pSPL3 plasmids containing  the wild-type or the variant  sequence were extracted using
PureYield Plasmid Midiprep System (Promega), and transfected into COS and HEK293
cells using the TurboFect kit (Fermentas, Vilnius, Lithuania). After 24h, total RNA was
extracted and retrotranscribed with the Cells-To-CT kit (Life Technologies). The cDNA
was sequenced using PCR vector  primers  (Fw: 5’-TCTGAGTCACCTGGACAACC-3’;
Rv: 5’-ATCTCAGTGGTATTTGTGAGC-3’). The expected final products were (Fig. 3.9):
1- a 263bp band resulting from the complete  skipping of the inserted exon, due to the
higher power of the vector splicing sites.
2- a 391bp band, resulting from the canonical splicing of HOGA1 exon 3
3- a 471bp band, resulting from the alternative splicing generated by the deletion of T in
c.341-81 
1) Vector exons A+B (263bp)
TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGCACTGTGACAAGCT
GCACGTGCTCTAGAGTCGACCCAGCAACCTGGAGATCTCCCGAGGGGACCCGACAGGCCCGAAGGA
ATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTTCGACCAATTCACTCCTCAGGTGC
AGGCTGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAATGCCCTGGCTCACAAATACCACTGAGAT
2) WT (391bp)
TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGCACTGTGACAAGCT
GCACGTGCTCTAGAGTCGACCCAGCACCACTCAAGCCACAGTGGAGATGACCGTCAGCATGGCCCA
GGTCGGGGCTGACGCGGCCATGGTGGTGACCCCTTGCTACTATCGTGGCCGCATGAGCAGTGCGGC
CCTCATTCACCACTACACCAAGACCTGGAGATCTCCCGAGGGGACCCGACAGGCCCGAAGGAATAG
AAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTTCGACCAATTCACTCCTCAGGTGCAGGC
TGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAATGCCCTGGCTCACAAATACCACTGAGAT
3) delT (471bp)
TCTGAGTCACCTGGACAACCTCAAAGGCACCTTTGCTAAGCTGAGTGAACTGCACTGTGACAAGCT
GCACGTGCTCTAGAGTCGACCCAGCACTGAGGCACCTTCGCTTGGCCCAGTGTCCTGGTCCAGGCC
TCCTTCTGCCTGCTCTCACCTCTCTCCTTCCTCTGGCAGCCACTCAAGCCACAGTGGAGATGACCG
TCAGCATGGCCCAGGTCGGGGCTGACGCGGCCATGGTGGTGACCCCTTGCTACTATCGTGGCCGCA
TGAGCAGTGCGGCCCTCATTCACCACTACACCAAGACCTGGAGATCTCCCGAGGGGACCCGACAGG
CCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTTCGACCAATTCACTC
CTCAGGTGCAGGCTGCCTATCAGAAGGTGGTGGCTGGTGTGGCCAATGCCCTGGCTCACAAATACC
ACTGAGAT
Figure 3.9: sequences of the expected products. Vector primers are highlighted in bold. The
insertion point between the vector exons A and B is highlighted in blue. HOGA1 ex 3 is
highlighted in green; in red the 79bp insertion expected from the generation of a novel
splice-site by the c.341-81delT variant.
Electrophoresis of cDNA products was performed on a 2% agarose gel and demonstrated
the presence of two bands at 263bp and 391bp; the expected band at 471bp wasn’t present.
These  showed  no  differences  between  post-transfection  wild  type  and  deleted  spliced
products (Fig. 3.10)
Figure 3.10: 2% agarose gel electrophoresis of the wild type and delT products. 
263 bp
391 bp
WT delT blankladder
3.3 - AGXT promoter analysis
Sato et al  described a functional AGXT promoter (with TATA boxes and INR initiator
elements) in the 5’-flanking region of human AGXT. 
The analysis was set up by Sanger sequencing and primers were designed on the sequence
of  chr2:241806700-241808285  (NCBI  built  GRCh37,  hg19).  Four  amplimers  were
designed.
Amplimers Lengt
h (bp)
Forward Primer Reverse Primer
Amplimer 1 426 TGAGCATGGCAGAAAAGGAA TCCTCCCTCCTGAGGCTGTAC
Amplimer 2 395 AAGTACCTCAAACAGGTCTCAA ATTTTCTCTCTAAATCCCGCTAC
C
Amplimer 3 542 TTTGATTGGCAACTGACTGAAGA ACGTCCAGCCCCTCTTATTCT
Amplimer 4 486 CAGGGTCAGCAAACCACAGT TGGCCAAAGCCTGGAATAT
Table  3.4: AGXT  promoter  PCR:  amplimers  length  and  forward  and  reverse  primers
sequences; sequencing primers in bold.
The genomic sequence was analysed in 4 amplimers as shown below:
AAAGGGAAAAACGTGACCTACCCCCCTGAACTCCCTTTCAGCAGCAAGTAGTCAGGCGCACTGGAC
ACCCCTCTTCACTGTGCCGTTTCCCCTTTCTTGAGACCCCAACAGGAAGCAGGTGGACATGAGCAT
GGCAGAAAAGGAAGGGTCAAAGATTTCACCAAGATATTTGTCAGAGGGAAAATGAGGACAGCAAAG
ATCACCTGGAGACCATCAAGCAGGCCCCAGGTGGGGTGGGTGGAGGGGAGCCTCTTTATTTGAGAA
ATGTAGAATGAATTAGACTTCCCTATTATCTAAAGTTGGCACCTGGTTCCAGGCCTCTTTTCAACC
TAAAACTTATACATAACTAGAATTTCTATACATCTCTGGAATGCAGCATGCTGAAACTCACTGTGC
AACCCCTGCCTTGTGTGTGTCTGTATACCATGCAGGTTTGCTTGCTAAATTGAGCCTGTAAACCAA
AAAGTACCTCAAACAGGTCTCAATTAATTTAGAAAGTTTTTGTTGCCAAGGCTAAGGATGCACCCG
TGGTACAGCCTCAGGAGGGAGGACATCCTTGCCAAGCTCAAGGGTGCACCCCTGACCACAAGGGCC
CAAGGTGGTCGGGGCACAGCTTGCTTTTATACATTTTAGGGAGATATGAGGCATCAATCAATACAT
GGGAGATTTACATTGGTTCCATCTGGAAGGGCGGGACAACTTGAATTGGGGGGCTTCCAGGTCATA
GGTAGATTTAAACATATTTTGATTGGCAACTGACTGAAGAATTATTATCAGCAGAAAGGAGTGTCT
GGGTTATGAAATAGGGGTTGCAGGGAGCAGATGATGCCTTCAGGTAGCGGGATTTAGAGAGAAAAT
AGATGGTAAATGCTTCCTATCAGACTTAAGGTCTATGTCGATGTTAATGCTGGGGGTTATGATGTG
GCATGGCCTGAACGTCTTCCGGGTTAAAGTTTAGAGCACCCTGGCGGACAGGGAACCCCATTCAGA
TGGTTGCTGGGGGGCCTTCGAATTTTATTTTTGGTTTACAAGCCTTCCCATCAGCTGCGCCAGGGT
CAGCAAACCACAGTCCATGGGCCCAATCTGGCCTGCCACCTGCTTTTTGTAAATAAAGTTTTATAG
GAACACGCCCACACCTCTGGCAGCTGCTTTGCAAGCACGCAGCAGGGTTGAGTTGTTGCAACATAG
ACCACAGGGCCTGCCAAGCCTCAATTATCTGTGCTCCGACCCTTTAAGAAACACTTCTCTCACCCC
TGAGCTAAGCAGAATAAGAGGGGCTGGACGTGCAGGACTCAGAGTGGGAGCGAGGAGGGCTGGGGT
GAGGACAGCTTTGTCACACTCTGTTTTTCTGTCACTCAGCCCTGGGGGCTCCCTCTGCCTGAGGGC
TTCGTCCCCTGCTGCCTGGCCGTGACCCGCAGCACAAGCACAGATAAGCCTCAGGGAACAAAAGGC
AGGGCTGCCACGGAAGCCCATCCACCAATCCTCACCTCTCACCTCTGTGTCCGCCCTGCTGGGAAA
TATTCCAGGCTTTGGCCAAGGCCAGTGCAGCCCCAGGTTCCCGAGCGGCAGGTTGGGTGCGGACCA
TG
DNA sequence of chr2:241806700-241808285 (NCBI built GRCh37, hg19); the 5’UTR is
highlighted in bold; in purple the ATG. The four primer pairs are highlighted in grey, red,
green and yellow. In light blue
Sequencing of the AGXT promoter in the above mentioned 15 patients revealed in two of
them two heterozygous novel  variants:  c.-647C>T and  c.-424C>T. Neither  variant  was
reported  in  dbSNP141,  1000Genomes  (http://www.1000genomes.org),  EVS  (Exome
variant server). We considered these variants not to be pathogenic since they do not lie in
any known regulatory site. The validity of this conclusion is limited by the scarce available
literature on the AGXT promoter that precludes comparison with more studies.
 Chapter 4
Primary Hyperoxaluria in Europe  
4.1- The OxalEurope Group
OXALEurope,  the  European  Hyperoxaluria  Consortium  was  founded  in  2008
(www.OxalEurope.org) in order to bring together expert European clinicians and scientists
involved in patient care and the study of the molecular pathology of primary hyperoxaluria.
The aims of the present consortium are:
-  To set  up a database of primary hyperoxaluria  patients  to  allow study of the natural
history of the diseases
- Empower research and retrieve patients through a network of experts
- Assessment of best treatment options
Currently,  17  University  Hospitals  or  research  institutes  from  8  European  countries
(France,  Germany,  Italy,  The  Netherlands,  Poland,  Spain,  Sweden  and  the  United
Kingdom) are members of the Consortium, which has its base at the University Hospital of
Cologne, Germany.
The first step was the development of the European PH registry, which is the basis for
research projects and could be a fundamental resource to feed the international liaison PH
database, in which the European and the US based Mayo Clinic Hyperoxaluria database
may join.
OxalEurope members obtained IRB approval for participation.
4.2- The European Registry
This  is  the  largest  database  of  PH1 patients  available  currently,  through pan-European
collaboration of centers of expertise for PH, some of which serve as diagnostic referral
centers for other non-European countries. 
The earliest diagnosis dates from 1980 and the database was frozen on 31 December 2010
for analysis. It comprises clinical, genetic and biochemical information from 526 patients
who fulfilled the following diagnostic criteria of PH1: 
a) mutations on both AGXT alleles; 
b) reduced AGT catalytic activity; 
c) hyperoxaluria with hyperglycolic aciduria as defined by age-related reference ranges ;
d)  ‘other’ category  included  plasma oxalate  >100 umol/L;  raised  plasma glycolate  ;  a
single mutant allele with associated hyperoxaluria and clinical symptoms; or presence of
abundant oxalate crystals in a renal biopsy.
The results  of the preliminary analysis  on the OxalEurope database were published by
Mandrile et al. . 
Patients and methods
Median follow-up was 11.5 years (I-III quartiles: 4.2-20.2). Family screening identified 74
patients  (14%) with a  median time to follow-up of 12 years (I-III  quartiles:  6.9-18.6).
Complete genotype data was available for 410 patients. Urinary oxalate results were not
included due to difficulties harmonizing submitted data. Time to follow-up was defined by
the interval from date of symptoms to date of last clinical visit or date of death. Renal
survival was calculated by the Kaplan-Meier method in a multivariate analysis adjusted for
age and gender, with patient data censored at last follow up. 
Pyridoxine responsiveness was recorded according to the clinician’s report. 
More than 140 AGXT mutations have been documented , resulting in a vast number of
defective enzyme phenotypes; the “Primary hyperoxaluria mutation database” is available
at:www.uclh.nhs.uk/OurServices/ServiceA-
Z/PATH/PATHBIOMED/CBIO/Pages/Phmdatabase.aspx
Mutations are spread along all the exons and most mutations are found in a wide range of
ethnic groups. In the genotype-phenotype analysis we grouped genotypes in three classes
according to the expected effect on the protein product (Figure 4.1):
1. p.Gly170Arg (G170R): associated with mitochondrial mistargeting when in cis with the
minor allele  
2. Other missense (M): missense and in frame ins/del that are unlikely to cause complete
lack of protein production.
3. Null (N): nonsense, frameshift and splice-site mutations, assumed to produce no protein
product.
Figure  4.1:  distribution  of  AGXT
mutations;  blue  character  indicates
Missense  mutations,  black  null
mutations,  light  blue  mistargetting
mutation.
The  effect  of  different  genotype  classes  on  time  to  ESRD  was  estimated  using  Cox
proportional hazards models with adjustment for gender. Proportional hazard assumption
was checked using the Grambsh and Therneau test. Continuous variables were expressed
as median and I-III quartiles as measure of variability; categorical variables were expressed
as percentages and absolute numbers. F Test was used to evaluate clinical variables among
genotype  groups.  Median  times  at  ESRD  and  at  symptoms  were  computed  for  each
genotype using the method of Kaplan-Meier and differences were assessed by the log-rank
test.
All statistical testing was conducted at the 0.05 level. PASW Statistics (version 20) and R
(version 2.13) statistical packages were used for analysis.
Clinical characteristics
The most frequent symptom at onset was urolithiasis: nephrocalcinosis and/or urolithiasis
occurred in 70% of patients (Table 4.1). Infantile onset of symptoms (<1 year) occurred in
29% (36.6% with  ESRD  at  diagnosis)  whereas  15% of  patients  experienced  the  first
manifestation in adulthood (>18y). Median age at diagnosis was 8y (interquartile range:
2.6-22.2) and 28% of patients were diagnosed beyond 18y. The clinical characteristics of
OxalEurope patients differ from those of the US registry data : the median age of first
symptoms was 3.9y compared with 5.5y; median age at diagnosis was slightly younger
(8.1y compared to 10y). While urolithiasis was the most common presenting symptom, it
was less common overall than in the US study where it accounted for 90% of presenting
symptoms. We analyzed PH1 patients exclusively, contrary to the US study that included
all  types of PH, and may explain the different  age of onset of symptoms between the
studies, whereas the relatively low number of patients presenting with kidney stones or
nephrocalcinosis may be due to the relatively high number of patients found by family
screening.
ESRD at diagnosis was present in 195 of 451 OxalEurope patients (43%, data not available
for  75  patients)  at  a  median  age  of  31.2y  (range:  11.5–40).  Of  patients  diagnosed  in
adulthood, 70% were in ESRD at the time of diagnosis, versus 29% of patients diagnosed
in childhood. These data indicate a considerable diagnostic delay; overall, 43% of patients
presented in ESRD in contrast to 20% reported in the US study although the median ages
of  US patients  were  slightly  lower  (23y  vs  31.2y  in  this  study).  ESRD was  also  the
presenting  feature  in  30% of  children.  Late  diagnosis  may  depend  on several  factors.
Firstly, detection of hyperoxaluria by metabolic analysis is less common in adult than in
pediatric practice. Secondly, some patients may only experience occasional stone passage
that  may  not  be  recognized  as  a  symptom of  primary  hyperoxaluria.  Thirdly,  delayed
diagnosis  may  be  due  to  cumbersome  biochemical  procedures  (collection  of  urine,
shipment of specimen) and the multisystem character of PH1 in advanced disease.
Table 4.1.  Clinical characteristics of PH1 patients and relatives in the OxalEurope cohort.
Number  of  patients/number  of  available  data  are  given  in  brackets.  For  continuous
variables: I quartile / median value / III quartile; range of values in brackets (last column).
N
Range
(years)
Gender:
males 57% (300/526)
females 43% (226/526)
Diagnosis based on: 
Genetic and enzyme analysis 37.2% (196/526)
Genetic analysis alone 47.2% (248/526)
Enzyme analysis alone 8.2% (43/526)
Urine analysis alone (oxalate, glycolate) 0.9% (5/526)
Other (e.g renal biopsy, high plasma ox-
alate)
6.5% (34/526)
Symptoms:
asymptomatic 4% (19/526)
urolithiasis 32% (171/526)
nephrocalcinosis 17% (88/526)
urolithiasis and nephrocalcinosis 21% (111/526)
other (urinary tract infection, hematuria,
failure to thrive)
8% (46/526)
recurrence post renal transplantation 3% (14/526)
unknown 15% (77/526)
Age at first symptoms: 0.7 3.9 9.3 (calculated on 446 pts) (0-66)
in patients presenting with urolithiasis 1.9 4.6 11.7 (calculated on 262 pts) (0-66)
in patients presenting post renal transplanta-
tion
6.8 15.0 27.0 (calculated on 12 pts)
(6-45.4)
Symptoms < 1 year 29% (131/446)
Age at diagnosis 2.6 8.1 22.2 (calculated on 456 pts) (0-72)
Diagnosis ≥ 18years 28% (128/456)
ESRD at diagnosis 43% (195/451)
ESRD at follow up 58% (267/458)
Death 14% (67/477)
Age at death 2.35 15.5 33.9 (data missing for 3 pts) (0.3-73.8)
Relatives (74 patients)
Age of first symptoms in relatives 0.3 3.9 7.1 (calculated on 58 pts) (0.3-7.1)
Age of diagnosis in relatives 1.6 6.8 16.0 (calculated on 72 pts) (1.59-16)
Age at ESRD in relatives 11.5 23.0 34.4 (calculated on 22 pts) (11.5-34.4)
The cumulative patient survival was 95, 93, 85 and 74% at 5, 10, 30 and 50 years of age
respectively. Sixty-seven (14%) patients died. Sixty-four (96%) were in ESRD. 
Among the 256 patients with preserved renal function at diagnosis (56%), 74 developed
ESRD thereafter (29%). At last follow-up, 267 patients were in ESRD (58%), with data on
renal function missing for 67 patients (Table 1).
Progression to ESRD was slightly, but not significantly, earlier in males than in females
(log-rank test p-value: 0.155; mean age at ESRD in males: 24.3; I-III quartile: 20.3-31.3;
females: 27.2; I-III quartile: 23.5-33.5).
Clinical features in 74 patients diagnosed by family screening
Median age at  diagnosis was 6.8y (I-III  quartile:  1.6-16).   At diagnosis,  18% of these
patients  were  asymptomatic;  renal  manifestations  included  urolithiasis  31%,
nephrocalcinosis  12%,  or  both  24%,  other  symptoms  8%  (recurrence  post  renal
transplantation 1%), unknown 5%. ESRD at diagnosis occurred in 16 % vs 43% of index
cases. At the end of follow-up, ESRD had occurred in 34% vs 58% of index patients.
Overall, median age at ESRD in the relatives was 23y (I-III quartile: 11.5-34.4). Median
ages at onset of symptoms, at diagnosis and at ESRD were not statistically different from
index cases (p 0.78, 0.78 and 0.71 respectively).
Genotype-phenotype correlations
Our data  confirmed  the  majority  of  known geno-phenotype  associations,  but  grouping
AGXT mutations in three genotype classes allowed us to found a difference, not previously
described, in clinical  outcome with respect to onset of ESRD associated with different
genetic subclasses. 
Not  surprisingly,  the  most  common pathological  variant  in  our  cohort  was the G170R
mutation accounting for approx 40% of alleles, with patients homozygous or compound
heterozygous  having  a  more  favorable  outcome  particularly  in  terms  of  pyridoxine
responsiveness, consistent with results of previous studies . 
Phenotype correlation of AGXT mutation classes
Among the clinical variables considered, age at onset of symptoms, age at ESRD and AGT
activity in liver biopsy were significantly different among the genotypes (Table 4.2).
Onset  of  symptoms  occurred  later  in  G170R  homozygotes  (median:  6y)  and  was
intermediate in G170R/N compound heterozygotes (median: 4y) compared with the lowest
values of N/N homozygotes (median: 3y) and M/N heterozygotes (median: 2y) (Table 4.2).
Table  4.2.   (following  page)  Main  clinical  features  for  each  AGXT  mutation  class
genotypes.  Number of patients  given in brackets.  For continuous variables:  I  quartile  /
median value / III quartile. p-value is calculated among all groups; all statistical testing
was conducted at the 0.05 level. Tests used: 1Pearson test; 2Kruskal-Wallis test
G170R/G170R
(71)
G170R/M
(32)
M/M
(116)
G170R/N
(61)
M/N
(42)
N/N
(88)
p
Gender:                                                      F 48% (34) 28% (9) 41%  (47) 33% (20) 52% (22) 43% (38) 0.1761
M 52% (37) 72% (23) 59% (69) 67% (41) 48%  (20) 57%  (50)
Age at diagnosis 6.4 29.9 46.1 2.1  8.4 25.7 1.8  7.7 17.9 4.3 16.1 34.7 1.8  6.0 16.7 1.0  5.7 11.2 <0.0012
Age at onset of symptoms 0.9  6.2 22.1 0.6  3.5 10.27 0.9  3.5 7.8 1.6  4.5 12.4 0.5 2.0 5.3 0.5 3.0 5.6 0.0232
Symptoms:                             Asymptomatic 8% (5) 0% (0) 6% (6) 0% ( 0) 0% (0) 8% (6) 0.021
Urolithiasis 48% (30) 37%  (10) 36% (36) 57% (31) 31% (11) 26% (19)
Nephrocalcinosis 11% (7) 19%  (5) 16% (16) 17% (9) 19% (7) 28% (21)
Urolithiasis AND nephrocalcinosis 23% (14) 26% (7) 32% (32) 9% (5) 28% (10) 26% (19)
Other 
(urinary tract infection, hematuria, failure to thr
ive)
10% (6) 15% (4) 6%  (6) 13% (7) 14% (5) 8% (6)
Recurrence post renal transplantation 0%  (0) 4% (1) 3% (3) 4% (2) 8% (3) 4% (3)
Age at ESRD 19.9 33.9 47.5 11.5 31.2 39.9 3.4 16.9 34.1
15.5 25.1
33.8
1.9 11.5
19.9
0.4 9.9 17.6 <0.0012
ESRD at diagnosis 49% (30) 35% ( 9) 41% (40) 52% (28) 46% (18) 42% (32) 0.6221
ESRD developed during follow-up 56% (35) 54% (14) 55% (56) 62% (34) 57% (23) 57% (43) 0.9761
AGT in liver (% activity) 12.7 33.0 43.0 6.2 13.0 18.0 0.0 3.3 9.0 5.4 6.5 16.0 0.0 2.3 7.3 0.0 3.6 6.9 <0.0012
Pyridoxine                                No response 40% (19) 47% (9) 43% (29) 52% (24) 67% (18) 54% (27) 0.1041
Response 60% (28) 47% (9) 54% (36) 43% (20) 33% ( 9) 36% (18)
Not treated 0% (0) 5% (1) 3% (2) 4% (2) 0% (0) 10% (5)
Figure 4.2: censored Kaplan-Meier curves for age at onset of ESRD for each genotype
class. Data was available for 355 patients, log-rank test p-value: <0.001.
Renal survival by censored Kaplan-Meyer analysis (Fig. 4.2) showed that having at least
one G170R allele was also associated with a slower progression to ESRD (33.9 years in
G170R/G170R, 31 years in G170R/M and 25 years in G170R/N heterozygotes) compared
with  N/N  homozygotes  (9.9  years).  M/N  heterozygotes  (11.5  years)  and  M/M
homozygotes (16.9 years) had intermediate values; such stratification of the ESRD risk
was  confirmed  by  gender-adjusted  Hazard  ratios  (Fig.  4.3).  However,  5/70  G170R
homozygotes  progressed  to  ESRD  early  (before  10  y),  possibly  reflecting  suboptimal
clinical management,  presence of unidentified comorbidity,  environmental factors, other
possible genetic modifiers, or a deletion/gross rearrangement of the second allele that may
remain undetected if only the index case is analyzed. 
Figure 4.3 Hazard Ratios of age at onset of ESRD adjusted for gender (estimated with Cox
Model). Reference group is G170R homozygotes. The following confidence levels are all
shown: 0.9, 0.95, and 0.99, using different tone of grey (from darkest to lightest). 
Null mutations were generally associated with a poor prognosis, in accordance with the
complete  lack of AGT protein.  Nevertheless,  in 14/88 N/N homozygous patients,  renal
function was preserved to at least 16 years; seven of these developing ESRD after 20 years
of age. Some N/N patients were even reported to be pyridoxine-responsive although it was
not clear whether the degree of response was as currently defined .  However, in some of
these cases pyridoxine may work on other possible glyoxylate-using enzymes.
In the present study M/M homozygotes had a better outcome than the N/N and G170R/M
heterozygosity was associated with a better outcome than G170R/N, likely due to residual
enzymatic activity of the M allele. The same holds true comparing M/N with N/N (table 2,
fig 2 and 3). This risk stratification indicates that at least  some missense mutations do
retain significant enzymatic function. In an attempt to highlight the effects of individual
missense mutations, we ordered the patients carrying the same mutation according to their
median age at onset and at ESRD, and compared the rank positions in the M/M, G170R/M
M/N series (Fig. 4.4). For both outcomes, the rank position of most mutations was similar
in the three series: indeed, it can be noted on simple inspection that mutations associated
with early progression to ESRD (e.g. p.Gly116Arg) are recurrent in the different series and
the same holds true for mutations ranked in the late progression  (e.g. p.Gly47Arg). The
similarity of the ranking position is statistically significant (age at onset: p=0.02, age at
ESRD: p=0.008).  This similarity of rank order of the missense mutations among the three
series  provides  suggestive  evidence  of  their  graded  residual  activity,  sometimes  well
correlating with AGT activity  in liver  and in vitro findings.   Our findings will  require
confirmation  as  the registry  expands.  The observed differences  in  age  of  onset  and of
ESRD could not be ascribed to previously known reasons, as for the majority of mutations
in vitro activity was reported to be very low (http://www.uclh.nhs.uk/phmd). 
Figure 4.4.  Ranking of patient subgroups carrying the same missense mutation ordered
according to their median a) age at onset and b) age at ESRD either in homozygous state
(left  panels),  compound  heterozygous  state  with  G170R (middle  panels)  or  compound
heterozygous with a null mutation (right panel). The number of patients with the relevant
mutation is given in parentheses. 
Missense mutations are coded as follow:
Code Mutation name One  letter
code
A p.Arg36Cys R36C
B p.Phe152Ile F152I
C p.Leu384Pro L384P
D p.Gly156Arg G156R
E p.Gly82Arg G82R
F p.Leu101Pro L101P
G p.Ile244Thr I244T
H p.Ala368Thr A368T
I p.Arg233His R233H
J p.Trp108Arg W108R
K p.Gly41Arg G41R
L p.Gly190Arg G190R
M p.Glu274Asp E274D
N p.Gly350Asp G350D
O p.Met195Arg M195R
P p.Ser218Leu S218L
Q p.Gly82Glu G82E
R p.Arg360Gln R360Q
S p.Cys178Tyr C178Y
T p.Asp201Glu D201E
U p.Glu95dup E95dup
V p.Met195Leu M195L
W p.Arg233Cys R233C
X p.Cys173Tyr C173Y
Y p.Ser275Arg S275R
Z p.Ser81Leu S81L
a p.Ile220Phe I220F
b p.Gly116Arg F116R
c p.Gly362Ser G362S
d p.Gly109Val G109V
e p.Thr70Asn T70N
f p.Leu153Val L153V
g p.Gly47Arg G47R
h p.Leu150Pro L150P
i p.Gly161Ser G161S
j p.Ser205Leu S205L
k p.Ile279Thr I279T
m p.Gly216Arg G216R
n p.Gln282His Q282H
o p.Gly41Val G41V
p p.Asp183Asn D183N

In addition to G170R, several other mutations that were found in significant numbers were
considered in either homozygous or compound heterozygous states:
p.Ile244Thr.  The  31  homozygotes  displayed  a  wide  age  range at  onset  (median:  5.8y,
range: 0-49) and of ESRD (median: 12y, range: 0-70). All four p.Ile244Thr/N compound
heterozygotes had a neonatal onset, one developed ESRD in the first months of life, while
three,  all  under  5y,  still  retain  renal  function.  Eight  of  the  nine  patients  who  were
pyridoxine  responsive  had preserved renal  function  (mean  age  at  last  follow up:  6.7y,
range: 1-17), whereas only three of the seven non-responsive patients had preserved renal
function (median age at last follow up: 5y, range: 1-38). 
The wide range of age of onset and of ESRD in p.Ile244Thr homozygous patients could be
due to the differences highlighted in functional studies, where it has been demonstrated
that  the  mutation  retains  significant  activity  when  expressed  on  the  major  haplotype,
whereas in association with the minor haplotype it negatively influences AGT stability .
p.Phe152Ile is  also associated  with a  wide age range at  onset  of symptoms in the six
homozygotes  (median 20y; range: 10 -  24),  in  the three compound heterozygotes  with
G170R (median: 14.5y; range: 1.5-26) and in the ten with a Null mutation (median: 0.2y;
range: 2-4.5). Three homozygotes developed ESRD after age 30y while the other three,
older than 16y, still have preserved renal function (mean age: 24y). This is similar to the
finding in p.Phe152Ile/G170R heterozygotes (age at ESRD: 36y in two patients and one,
age 12y, with preserved renal function). Overall,  there was a much later onset of renal
impairment in this group.
The p.Phe152Ile AGT mutant forms aggregates and needs to be continuously supplied with
pyridoxine to remain in a catalytically competent form . When p.Phe152Ile is associated
with  the  minor  allele  mitochondrial  mistargeting  occurs.  In  accordance  with  these
functional studies , we observed a relatively mild disease associated with this mutation.
p.Met195Arg. The ten homozygotes had early onset of symptoms (median: 2y, range: 0-3)
but similar age at ESRD compared to other mutations (median: 16y, range: 9-22) and two
patients have preserved renal function at 20y and 16y.
p.Asp201Glu. Five out of seven homozygous patients presented early (median age at onset:
0.5y, range: 0.5-2.7) but retained kidney function at  last  follow up (median age at  last
follow  up:  13y,  range:  4-15  y).  The  two  other  homozygotes,  with  neonatal  onset  of
symptoms,  developed  early  ESRD  (3  months  and  1  year  respectively).  The  single
heterozygous p.Asp201Glu/N patient has preserved kidney function at last follow up (10y).
p.Ser81Leu is associated with an earlier onset of ESRD when in compound heterozygosis
with a  Null  mutation  (two patients  with  ESRD at  10 and 14 y)  than  with a  p.G170R
mutation (2 patients older than 20 y with preserved renal function). Our clinical findings
support a loss of function for p.Ser81Leu, predicted by in silico analysis to result from
impaired pyridoxine binding.
p.Arg36Cys. The  two  homozygous  patients  and  two  p.Arg36Cys/G170R heterozygotes
display  a  wide  range  of  onset  ages  (3,  6,  17,  58  years)  but  late  ESRD  (the  two
homozygotes at 58y; one p.Arg36Cys/G170R at 67y and the other one with preserved renal
function). No compound heterozygotes with a Null mutation were present in the database.
The better clinical outcome in all three patients well correlates with the  partial catalytic
activity shown in the in vitro studies, especially on the major allele . 
 Most, but not all of the missense mutations have now been expressed  in vitro and the
majority  have  little  activity  when  expressed  on  the  minor  allele
(http://www.uclh.nhs.uk/phmd and ) but some have significant activity on the major allele.
Unfortunately  the  polymorphism  status  for  many  of  our  patients  was  unknown  and
therefore in most cases it was not possible to assess whether the polymorphic background
contributed to a milder phenotype.
The partial discordance between early functional studies and our clinical findings could be
related to limitations of  in vitro studies and suggests that new techniques are needed to
better explore the folding dynamics of AGT and the molecular basis of the disease . The
cellular assay first described by Danpure and colleagues  and recently updated  is expected
to contribute to a more accurate assessment of the residual function of different mutations.
Chapter 5
The Telethon project
In collaboration with Prof. Borri-Voltattorni’s group (University of Verona) we developed a
Telethon  project  (GGP10092),  aiming  to  improve  the  clinical  management  of  patients
affected  by  Primary  Hyperoxaluria  Type  I  (PH1)  by  exploiting  the  knowledge  on  the
genotype-enzymatic  phenotype-clinical  phenotype relationships  to develop new specific
and non-invasive treatment strategies. 
Although  PH1  is  characterized  by  a  significant  variability  in  terms  of  enzymatic
phenotype, the majority of the pathogenic variants are believed to share both structural and
functional defects, as mainly revealed by data on AGT activity and expression level in
crude cellular extracts. However, the knowledge of the defects of the AGT variants at a
protein level is still poor. Therefore, in the Telethon project several AGT mutations were
studied in vitro . 
In an attempt to shed light on the mechanisms leading to PH1, we focused our attention on
the molecular defects underlying AGT deficiency in compound heterozygous patients. Like
in other recessive diseases, many PH1 patients are compound heterozygous expressing two
different  AGT alleles.  In  these  patients,  interallelic  complementation  (IC)  phenomena
could occur, leading to a phenotype less severe (positive IC) or a more severe (negative IC)
phenotype than that of the homozygous counterparts. IC effects arise from the combination
of monomers bearing different mutations yielding heterodimeric species with functional
and/or structural properties different from the average of those of parental homodimers.
Until now, only “single protein” studies have been undertaken to investigate the molecular
pathogenesis  of  PH1,  and  the  possible  interplay  between  two  different  pathogenic
mutations  at  clinical  and enzyme  level  has  never  been  analysed.  We started  from the
clinical data on two PH1 patients, one hemizygous for the S81L mutation associated with
the major allele, and the other compound heterozygous for the S81L mutation on the major
allele and the most common mutation in Caucasian patients, i.e. the G170R associated with
the minor allele (See Appendix 1).
In order to develop new treatment strategies, less invasive and effective for all the patients,
our planning act followed two approaches, the first based on enzyme enhancement and the
second based on enzyme administration.
Studies performed in the last years, along with the results obtained during this project, have
highlighted that in many cases PH1 can be considered a misfolding disease. In fact, many
mutations induce subtle conformational changes leading to a variety of downstream effects
including an increase in the aggregation propensity, a decreased stability of the dimeric
structure and an enhanced susceptibility to intracellular degradation. One of the approaches
currently  under  investigation  to  treat  misfolding  diseases  is  the  enzyme  enhancement
therapy,  which  is  based  on  the  use  of  pharmacological  chaperones.  Pharmacological
chaperones are small molecules able to specifically bind a mutated protein and to shift the
equilibrium toward the attainment of the native structure. In case of diseases caused by
enzymatic  deficits,  molecules  acting  as  pharmacological  chaperones  are  competitive
inhibitors, which specifically bind the enzyme active site and are able to dissociate in the
presence of the physiological substrate. Thus, in an attempt to identify molecules acting as
pharmacological chaperones for AGT variants showing folding defects,  we focused our
attention on aminoxyacetic acid (AOA) a known competitive inhibitor of AGT. We studied
the interaction  of  AOA with AGT-Ma,  AGT-Mi and the  pathogenic  variants  G41R-Ma
(characterized by an increased intraperoxisomal aggregation propensity), G170R-Mi (the
most  common  variants  associated  with  mitochondrial  mistargeting)  and  I244T-Mi
(characterized  by  a  partial  mitochondrial  mistargeting  and  an  increased  aggregation
propensity).  Moreover,  we  analysed  the  effects  of  the  presence  of  AOA in  a  well
established disease model based on CHO-GO cells stably expressing AGT-Ma, AGT-Mi or
the  pathogenic  variants  G41R-Ma,  G170R-Mi  and  I244T-Mi.  The  results  of  our
investigations allowed us to conclude that: 
- AOA behaves as a competitive slow, tight-binding inhibitor of the analysed enzymatic
species
- AOA is able to act as a pharmacological chaperone for the pathogenic variants because it
decreases  the  aggregation  propensity  of  G41R-Ma  and  promote  the  peroxisomal
localization of G170R-Mi and I244T-Mi. These results provide the proof-of-principle that
an enzyme enhancement therapy for PH1 could be possible and constitute the base for the
identification  of  molecules  more  specific  for  AGT.  In this  regard,  large  scale  in  silico
screening of libraries of commercially available compounds are ongoing.  
Since PH1 originates from the deficit of a single enzyme, the opportunity to restore the
catalytic  pool  of  the  hepatocytes  by  administering  exogenous  enzyme  is  an  intriguing
perspective.  However,  two  of  the  major  issues  for  the  development  of  an  enzyme
administration therapy is the obtainment of large amounts of pure protein from eukaryotic
sources and the intracellular  delivery of the exogenous protein.  During our project,  we
setup a protocol to purify recombinant AGT from CHO cells stably expressing the AGXT
gene. We obtained about 1 mg of pure protein from 1L of cellular culture.  In order to
obtain  an  AGT able  to  cross  the  plasma  membrane,  a  dual  approach  was  used:  the
construction of a fusion protein between AGT and the Tat peptide exploiting the membrane
crossing  capabilities  of  the  Tat  moiety,  and the  conjugation  of  AGT with  a  polymeric
nanocarrier  made  of  PEGylated-poliglutammic  acid  (PEG-PGA)  able  to  deliver  the
functional enzyme across the plasma membrane. We found that neither the fusion with the
Tat peptide nor the conjugation with PGA-PEG significantly affect the spectroscopic and
kinetic properties of AGT. Both strategies proved to be effective in transducing active AGT
into CHO-GO cells in a time-dependent and concentration-dependent manner. Moreover,
the transduction of CHO-GO cells with Tat-AGT or with PEG-PGA-AGT is able to restore
the ability of the cells to detoxify intraperoxisomal glyoxylate. An important question still
remains  open  concerning  the  achievement  of  the  correct  peroxisomal  localization  of
transduced AGT. 
Thus, both Tat-AGT and PEG-PGA-AGT conjugates possess the basic requisites for the
development of a therapy based on the intracellular delivery of functional enzyme, thus
possibly rescuing for the enzymatic deficit of PH1. It should be considered that the two
approaches  present  different  strength.  The  Tat-AGT fusion  protein  is  a  more  simple
solution but the presence of the Tat tag does not confer any protection against the possible
degradation of AGT in the bloodstream and has the major shortcoming of the possible
induction  of  an  immune  response  for  long-lasting  treatments.  On  the  other  hand,  the
deployment of a polymeric carrier  conjugated to AGT adds a layer of control over the
stability of the conjugate and its targeting properties. In fact, the polymer moiety is known
to increase the stability of proteins in physiological fluids and it can be modified ad hoc to
direct the protein to a particular tissue. Thus, PEG-PGA-AGT should be regarded as the
preferred strategy to be implemented for the development of an enzyme administration
therapy for PH1. 
Finally,  it  should  be taken into account  that  CHO-GO cells  only represent  an in  vitro
disease model and that the physiological localization of AGT are hepatic cells. Thus, our
future goals will be to test the ability of the fusion protein and the conjugates both to be
internalized in cellular models of hepatic cells, such as HepG2, and to localize in the liver
of a mouse disease model. 
Chapter 6 
General discussion and conclusions
Primary  Hyperoxaluria  is  a  disease  with  a  broad  range  of  clinical  symptoms  and  the
molecular mechanisms leading to the disease are not fully described.
In this  PhD thesis  some contributions  were made to  the  general  understanding of  this
disease,  both  as  regards  the  genotype-phenotype  correlations  and  as  functional
characterization of AGXT mutations.
A grey zone of cases in which suspicions based on clinical and biochemical findings are
not  confirmed by genetic  testing  is  recognized in  the  diagnostic  practice  of  most  rare
genetic diseases and in PH1 as well. To clarify the inconclusive diagnoses in our historical
series of cases referred for genetic diagnosis of PH we selected  15 patients with primary
oxaluria,  AGXT mutation-negative, to address to the analysis of the  AGXT-promoter and
the additional known genes GRHPR and HOGA1.  Our analyses did not provide evidence
of pathogenic mutations of these genes in any of the 15 patients.
In two patients we identified two novel heterozygous AGXT-promoter variants, c.-647C>T
and c.-424C>T. We considered these variants not to be pathogenic since they do not lie in
any known regulatory site. The validity of this conclusion is limited by the scarce available
literature on the AGXT promoter that precludes comparison with more studies.
In one patient we detected a novel homozygous HOGA1 variant in intron 2 (c.341-81delT),
not reported in literature. The sequence of intron 2 is highly conserved among primates but
not in other species (http://genome.ucsc.edu/cgi-bin/hgc), and thus it can be hypothesized
to play a role for HOGA expression and activity in primates, including humans. Neither
RNA nor HOGA enzymological studies were possible for lack of biological samples of the
patient;  thus,  to  evaluate  the effect  of  the  variant  we set  up a  minigene  assay,  that  in
contrast to in silico predictions, did not reveal any difference between the product of wild
type and c.341-81delT variant constructs. A possible explanation is that the power of the
splicing site may be weaker than the canonical splicing site, so it could not be revealed by
the simple minigene protocol in COS-7 and HEK293T cells. Despite these limitations, this
report could be a useful base for further functional studies of this variant.  
Since oxalate metabolism is complex and not fully described, it is possible that other genes
are presently uncovered and even a multiallelic PH inheritance has been suggested. Among
PH candidate genes, the three human lactate dehydrogenases (LDHA, LDHB, LDHC) have
an important role in excessive oxalate production: LDH is able to convert glyoxylate in
oxalate,  glyoxylate  in glycolate  and hydroxypyruvate in L-glycerate,  using NAD(H) as
cofactor. In the future, next generation sequencing could be a useful tool to both discover
novel genes involved in glyoxalate metabolism and PH phenotype modifiers.
Thanks to the collaboration with Prof. Borri-Voltattorni's group, we were able, for the first
time, to understand the effects of the S81L mutation on the major allele and the G170R on
the minor allele under homozygous and heterozygous conditions. Our investigation was
not limited to the AGT activity of the purified recombinant forms of S81L-Ma, G170R-Mi
and S81L-Ma/G170R-Mi and to the specific activity upon expression or coexpression of
the S81L and G170R variants in CHO cells, but was extended to their expression level,
coenzyme binding affinity, subcellular localization and functionality. This broad spectrum
analysis resulted to be useful considering the multiplicity of the molecular mechanisms
accounting for AGT deficiency.  The results  gave new significant  insights into the PH1
mechanism, as we report the molecular basis of the pathogenicity of the S81L mutation on
the major allele and the interplay between this mutation and the G170R mutation on the
minor  allele.  When expressed  individually  the  S81L-Ma and G170R-Mi variants  show
distinct features. As already reported and confirmed in this study, when only G170R-Mi
allele is expressed, AGT retains catalytic activity and PLP binding affinity, but it is almost
completely  redirected  to mitochondria  .  On the other  hand, we reported that  when the
S81L-Ma allele (lacking the putative MTS) is expressed, AGT shows a decreased catalytic
activity, is almost completely present in the apo form, and is mainly peroxisomal. Thus,
while the pathogenicity of the G170R mutation is related to AGT mistargeting, that of the
S81L mutation is linked to the reduction of PLP binding affinity. We were able to recreate
the  naturally  occurring  mutations  S81L and  G170R  in  AGT identified  in  compound
heterozygous  patient  and  to  isolate  and  characterize  the  heterodimer  in  the  purified
recombinant form. This allowed us to establish that it exhibits a considerable kcat value and,
in agreement with its KD(PLP) value, it is present in the cell mainly in the holo form. More
importantly,  it  shows  a  peroxisomal  localization.  The  peroxisome-to-mitochondrion
mistargeting of AGT in PH1 is due to the combined effects of (i) the generation of a MTS
resulting from the P11L polymorphism, and (ii) the presence of monomeric AGT. Since in
the heterodimer G170R-Mi/S81L-Ma only the first condition occurs, even if limited to one
subunit, its peroxisomal localization is not surprising. It can be also speculated that in cells
expressing both S81L-Ma and G170R-Mi the rate of the formation of the heterodimer is
faster  than  that  of  the  import  of  G170R-Mi  monomers  in  mitochondria.  Moreover,
although cells expressing both G170R-Mi and S81L-Ma show a reduced expression level,
they  display  an  ability  to  detoxify  glyoxylate  greater  than  that  of  cells  expressing
homodimer S81L-Ma and equal to those expressing homodimers G170R-Mi. In the first
case, this could be interpreted on the basis of the significant amount of protein present in
the holo-form. In the second case, the detoxification ability could be ascribed to the proper
subcellular localization of the heterodimer. 
All  together,  these  results  indicate  that  the  association  between  the  G170R and  S81L
monomers leads to a global positive IC between these mutations. The clinical data reported
in  this  study  appear  to  agree  with  our  biochemical  data:  the  G170R/S81L compound
heterozygous  patient  had  a  late  onset  of  ESRD  compared  with  the  one  functionally
hemizygous for the S81L mutation who only expresses the S81L-Ma variant.
This work constitutes a valid example of an approach useful to understand the enzymatic
phenotype  in  compound  heterozygous  PH1 patients,  with  potential  applications  to  the
study of the interaction between other pathogenic mutations. Besides providing a better
knowledge of the disease pathogenesis, the results obtained could allow to develop proper
therapeutic treatments, as the hybrid protein could have defects different from those of the
parental enzymes.
The genotype-phenotype studies  were made  possible  by the  collaboration  with  several
European Centres,  all  being part of the OxalEurope group. The decision to assemble a
common database allowed the formation of the largest PH1 registry worldwide. Thanks to
the  high  number  of  patients  and  the  use  of  a  standardized  form for  data  collection  it
promises not only a detailed description of PH1 across European populations, but also a
unprecedented  possibilities  for  drawing  genotype-phenotype  comparisons  and  defining
shared guidelines for diagnosis and treatment. In addition, in the next years it may become
the instrumental basis to address a variety of issues of clinical and genetic interest such as
the epidemiology of PH, the mutational spectrum, treatment regimen, disease progression,
inter-population comparisons and many others.
As regards the clinical findings, it is relevant to note that the disease is largely diagnosed in
later stages, frequently after renal failure or even after a renal transplant, which is soon
damaged by oxalate deposition.  As early conservative treatment may delay renal damage,
particularly in pyridoxine responsive patients, metabolic screening for all children at first
presentation of a kidney stone or nephrocalcinosis, and for all adults with recurrent stone
disease, might be a most important recommendation.
As for transplant strategies is not jet possible to define strong recommendation,  further
analyses will be performed.
As for genotype-phenotype analysis, we decided to classify mutations in classes, similarly
to what is usually done for Cystic Fibrosis , in order to limit the number of comparisons
that  would  otherwise  have  limited  the  statistical  strength  even of  the  large  number  of
patients of the OxalEurope registry.
Some correlations  already suggested are confirmed:  mistargeting mutation has a higher
AGT activity,  later age at onset and at  ESRD, better response to pyridoxine and lower
levels  of  urinary  oxalate.  Moreover,  even  if  the  disease  eventually  leads  to  ESRD,
genotypes with a significant residual enzymatic activity are on average associated with a
longer disease free period. 
However a minority of patients, five in OxalEurope cohort, had an early progression to
ESRD. These patients are shown in the figure 7.1 and are one German with ESRD at 1
year, one Dutch with ESRF at 3 years, a German and a French with ESRD at 5 years and a 
German with ESRD at 10 years.
Figure 7.1: focus on patients with a progression to ESRD within 10 years of age.
This finding deserves a further check of the real genotype, in particular testing for large
gene deletions,  in  order  to evaluate  if  a hemizygosis is  present,  that  could explain the
worse  clinical  course  because  these  patients  would  be  re-classified  as  a  heterozygotes
G170R/N.
A late age at onset of ESRD in some patients homozygous for a null mutation and an early
onset in some G170R homozygotes has already been reported and ascribed to other factors
different from AGXT genotype .
Having at  least  one allele  with a  mistargeting  mutation  is  sufficient  to confer  a  better
course to the disease, probably thanks to a significant level of residual enzyme addressed
to the peroxysome.
On the contrary, some missense mutations are frequently associated with an early onset of
ESRD, probably depending on the structural alteration induced by the mutation. 
In  conclusion,  this  study  of  an  unprecedented  number  of  PH1 patients  showed  geno-
phenotype associations that have not been previously described. These findings may have
important implications for the management of PH1 patients and underline the necessity of
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genotyping PH patients, including unambiguous assignment of minor/major allele status.
We also identified considerable diagnostic delay in this disease, which may partly explain
the overall adverse outcome in some patients. A limitation of this first report is the absence
of some clinical data and the lack of systematic nationwide data collection, accounting for
the inability to provide precise prevalence and incidence estimates. Moreover, pyridoxine
sensitivity  was  not  formally  tested  as  is  now  recommended  .  Notwithstanding  these
limitations, this report shows that the OxalEurope database, with establishment of regular
data input, will represent an invaluable resource for delineating genotype-phenotype and
other clinically relevant issues in PH. Moreover, the database will provide the backbone to
design future therapies and conduct prospective clinical trials in PH ultimately providing
personalized medicine to this devastating metabolic disease.
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Abstract
Primary hyperoxaluriaType1isarareautosomal recessive
inborn error of glyoxylate metabolism, caused by a defi-
ciency of theliver-specificenzymealanine:glyoxylateami-
notransferase. The disorder results in overproduction and
excessive urinary excretion of oxalate, causing recurrent
urolithiasis and nephrocalcinosis. As glomerular filtration
ratedeclinesdueto progressiverenal involvement, oxalate
accumulates leadingto systemic oxalosis. Thediagnosis is
based on clinical and sonographic findings, urine oxalate
assessment, enzymology and/or DNA analysis. Early ini-
tiation of conservative treatment (high fluid intake, pyri-
doxine, inhibitors of calciumoxalate crystallization) aims
at maintaining renal function. In chronic kidney disease
Stages 4 and 5, the best outcomes to date were achieved
with combined liver–kidney transplantation.
Keywords: combined liver–kidney transplantation; nephrocalcinosis;
oxalosis; primary hyperoxaluria type1; urolithiasis
Introduction
The term ‘primary hyperoxaluria’ (PH) encompasses an
indeterminatenumber of rareautosomal recessivecalcium
oxalate kidney stone diseases, of which three have been
described at the molecular level. PH1 is caused by muta-
tions in the AGXT gene, which lead to dysfunction of the
vitamin B6-dependent liver-specific peroxisomal enzyme
alanine:glyoxylate aminotransferase (AGT) [1, 2]. PH2
arises frommutations in theGRHPR geneand subsequent
dysfunction of the enzyme glyoxylate/hydroxypyruvate
reductase(GRHPR) [3–5]. PH3 is caused by mutations in
the HOGA1 gene, which is thought to encode the mito-
chondrial enzyme4-hydroxy-2-oxoglutaratealdolase[6].
ThispaperfocusesonPH Type1(PH1, OMIM 259900),
the commonest form of PH. The clinical presentation
ranges fromasymptomatic through to isolated or recurrent
renal stones, nephrocalcinosis and renal impairment. The
heterogeneous presentation leads to adiagnostic challenge
andtherefore, specificbiochemical andgeneticassessment
is required to confirm a diagnosis of PH1 and to institute
appropriatetreatment.
Materials and methods
PH1 is avery rare inherited disease with a limited access to recommen-
dations for diagnosis and management, due to the lack of randomized
clinical trialsandmeta-analyses. Anexpertgroup(OxalEurope) hasthere-
forebeenestablished to providediagnostic and therapeutic recommenda-
tions for patients with PH. Experts wereselected on both their individual
commitment and their peer-reviewed publication activity in this field.
Number of PubMed papers were (MeSH: hyperoxaluria, October 2011):
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